奥曲肽联合奥美拉唑对急性胰腺炎患者胃肠激素及肠道黏膜屏障功能的影响

表3 两组急性胰腺炎患者治疗前后肠道黏膜屏障功能比较 [n = 62, (mean±SD)]

分组	时间	ET (ng/L)	DLA (μg/L)	DAO (U/L)	AMY (U/L)
观察组	治疗前	92.15 ± 12.24	11.24 ± 1.45	18.12 ± 2.45	620.25 ± 72.12
	治疗2 wk	53.12 ± 7.25ac	4.45 ± 0.78bd	6.47 ± 1.12bd	124.36 ± 24.35bc
对照组	治疗前	91.74 ± 13.12	12.10 ± 1.34	17.65 ± 3.20	618.45 ± 74.21
	治疗2 wk	64.20 ± 7.36a	6.42 ± 0.86a	9.10 ± 1.26a	160.21 ± 26.54a

两组治疗前比较, t = 0.180, 0.558, 0.918, 0.137;

^bP<0.01, 观察组治疗前、治疗2 wk比较, t = 14.415, 23.539, 19.324, 51.324;

^cP<0.05,

^dP<0.01, 两组治疗2 wk比较, t = 8.445, 13.360, 12.284, 7.818; ^fP<0.01, 对照组治疗前、治疗2 wk比较, t = 14.415, 23.539, 19.324, 45.791. ET: 血清内毒素; DLA: D-乳酸; DAO: 二胺氧化酶; AMY: 淀粉酶.